Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- TOPICS 2 articles
March 2, 2009
- Chugai Licenses Nitazoxanide from Romark Lab.
March 2, 2009
- Acquisition of Local Company an Option for Marketing Lurasidone in US: DSP
March 2, 2009
- GSK to Tie Up with Nippon Kayaku to Market Lapatinib in Japan
March 2, 2009
- Mr Shoda Feels the Pinch of the Global Financial Crisis
March 2, 2009
- BUSINESS NEWS IN BRIEF
March 2, 2009
- Korosho Suggests Re-Pricing Based Only on Increases in Sales
March 2, 2009
- Reductions in Makers' Invoice Prices Have Not Been Sufficient
March 2, 2009
- JGA Prepares Tools for Education of MRs from Its Member Companies
March 2, 2009
- REGULATORY NEWS IN BRIEF
March 2, 2009
- MEDICAL DEVICE NEWS IN BRIEF
March 2, 2009
- Bayer Yakuhin: Wellnara for Postmenopausal Osteoporosis
March 2, 2009
- Skirmishes Heat Up between Pro- and Anti-Online Drug Sale Camps
March 2, 2009
- Project Begun in Order to Verify Usefulness of MD Studies
March 2, 2009
- Group of LDP Lawmakers to Draft Bill to Restrict Online Sale of OTC Drugs
March 2, 2009
- Shionogi's Velneperit Meets Primary Endpoint in 2 PIIb Trials
March 2, 2009
- Gov't to Issue Action Program and GL for New-Type Influenza
March 2, 2009
- R&D NEWS IN BRIEF
March 2, 2009
- PMDA Announces Draft of 2nd Mid-Term Plan
February 23, 2009
- FDA Approves Gout Treatment from Teijin/Takeda
February 23, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…